6533b7dbfe1ef96bd1270a66

RESEARCH PRODUCT

Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion.

Manuel Díaz-llopisRosa Dolz-marcoCristina Marín-lambíesR. Gallego-pinazo

subject

medicine.medical_specialtyRetinal Veingenetic structuresReviewlaw.inventionRandomized controlled triallcsh:OphthalmologylawOphthalmologyOcclusionMedicineIn patientranibizumabMacular edemaIntravitreal triamcinolonemacular edemabusiness.industrymedicine.diseaseVEGFeye diseasesantiangiogenic therapylcsh:RE1-994retinal vein occlusionRetinal vein occlusionsRanibizumabbusinessBiomedical engineeringmedicine.drug

description

Macular edema is the leading cause of visual impairment in patients with retinal vein occlusion. Limited improvements may be obtained with laser photocoagulation or intravitreal triamcinolone. However, according to the data provided by randomized clinical trials, intravitreal injections of ranibizumab (Lucentis; Genentech, South San Francisco, CA) constitute a new effective and safe option for the management of these vision-threatening diseases. The aim of the present review is to summarize the clinical evidence of ranibizumab for macular edema due to retinal vein occlusions.

10.4137/oed.s7264https://pubmed.ncbi.nlm.nih.gov/23650454